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Long-term evolution of cardiomyopathy in dialysis patients
Background. Left ventricular enlargement is very common at
the inception of dialysis therapy, and highly predictive of future
cardiac morbidity and mortality. It is not known whether cardiac
size increases further while on dialysis therapy and whether
potentially reversible risk factors for later progression can be
identified.
Methods. Baseline and yearly echocardiograms were performed
in a prospective inception cohort of 433 dialysis patients. The
mean patient follow-up was 41 months; 29 patients had four
consecutive echocardiograms at yearly intervals.
Results. The patient subset with four echocardiograms was older
(58 vs. 51 years, P 5 0.02) and had a lower mass ventricular mass
index (128 vs. 149 g/m2, P 5 0.02) than the parent group. Using
repeated measures analysis of variance, applied to those with four
echocardiograms, there were progressive increases over time in
posterior wall thickness (P 5 0.015), left ventricular end-diastolic
diameter, left ventricular mass index (P 5 0.001), and cavity
volume index (P 5 0.001). Mass-to-volume ratios did not change.
The biggest changes in mass (18 g/m2 2 14%)and volume index
(13 ml/m2 2 18%) occurred between baseline and year 1,
although increases in both were seen after year 1. Hemodialysis
versus peritoneal dialysis (41 g/m2, P 5 0.008) and anemia (10
g/m2 per 1 g/dl drop in hemoglobin, P 5 0.02) were associated
with progressive left ventricular enlargement, but only within the
first year of dialysis therapy. The left ventricular enlargement seen
after year 1 was independent of anemia, blood pressure, serum
albumin and mode of dialysis.
Conclusions. Progressive cardiac enlargement, particularly left
ventricular dilation with compensatory hypertrophy, continues
after starting dialysis therapy. Most of the additional cardiac
enlargement seems to occur in the first year of dialysis therapy,
suggesting that intervention beyond one year may be relatively
ineffective.
Cardiac disease is responsible for about half of all deaths
in dialysis patients [1, 2]. Cardiac failure in particular has a
very poor prognosis, approximately doubling mortality
rates [3, 4]. About three quarters of end-stage renal disease
patients starting dialysis therapy have left ventricular hy-
pertrophy, left ventricular dilation or low fractional short-
ening [5]. This cardiac enlargement appears to progress
rapidly as renal function declines [6–8]. In dialysis patients
it appears to be strongly predictive of developing clinically-
defined ischemic heart disease and cardiac failure for the
first time, and is ultimately predictive of higher mortality
[9].
Considerably less is known about the long-term natural
history of cardiomyopathy in dialysis patients. In particular,
it is not known whether cardiac size and function improve
or degenerate while on dialysis therapy, and whether
reversible risk factors for later progression are similar to
those associated with early progression, such as anemia and
hypertension [6–8]. In this study, we report the evolution
and risk factors of early and late progression in a group of
dialysis patients who had four consecutive echocardio-
grams, at inception of dialysis and at yearly intervals
thereafter.
METHODS
Patients
This prospective cohort study of 433 patients started in
the Royal Victoria Hospital Montreal, Quebec in 1982, in
the Health Sciences Centre, St John’s, Newfoundland in
1984, and in the Grace Hospital, St. John’s, Newfoundland
in 1985. Patients were eligible for entry to the study if (a)
they survived for six months and (b) if they had a technically
satisfactory echocardiogram within a year of starting renal
replacement therapy. Patient recruitment finished in June
1991. The mean patient follow-up was 41 months.
Data collection
At baseline, and at yearly intervals thereafter, a clinical
assessment was undertaken to detect the presence of
cardiovascular disease. At monthly intervals the data col-
lected included blood pressure, hemoglobin and serum
albumin levels. A detailed description of the design and
definitions used in this study has been published elsewhere
[5].
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Echocardiography
Echocardiography was performed close to inception of
dialysis therapy and was scheduled to take part at annual
intervals. For this study we selected those 29 patients
patients still remaining on dialysis with four consecutive
echocardiograms. The echocardiograms were performed at
mean time intervals of 2, 18, 30 and 43 months, respec-
tively, following the inception of dialysis therapy. Left
ventricular mass index was calculated according to the
Penn convention [10]. The formula of Pombo, Troy and
Russell was used to calculate cavity volume, which was also
indexed to body surface area [11].
Analysis
Repeated measures analysis of variance was used to test
whether cardiac dimensions changed overall with time.
Bonferroni correction for multiple comparison was applied
when when looking at the differences between the first and
second, second and third, and third and fourth echocardio-
grams.
We measured mean monthly hemoglobin levels, predom-
inant mode of dialysis therapy, systolic and diastolic blood
pressure and serum albumin levels between the first and
second, second and third, and third and fourth echocardio-
grams. We then used linear regression analysis to test for
association between these time-averaged variables, and the
difference between the left ventricular mass index from the
first and second echocardiogams. Similar analyses were
performed looking at the differences between the second
and third and between the third and fourth echocardio-
grams.
RESULTS
Baseline characteristics
The baseline characteristics of the patient subset who
subsequently had four consecutive echocardiograms are
illustrated in Table 1. This patient subset was older (58 vs.
51 years, P 5 0.02) and had lower echocardiographic LV
mass index than (128 vs. 149 g/m2, P 5 0.02) than the
parent subset.
Characteristics while on dialysis therapy
The treatment characteristics of the 29 patients with four
consecutive echocardiograms are shown in Table 2. It is
noteworthy that these patients had reasonable blood pres-
sure values, within a relatively narrow range.
Evolution of echocardiographic parameters
Left atrial dimension and fractional shortening remained
relatively constant over time (Table 3), and there was a
clear tendency for both LV cavity volume and LV mass
index to increase over time (P , 0.001). Mass/volume ratios
remained constant, suggesting that the dominant evolution-
ary picture was of progressive LV dilation with compensa-
tory LV hypertrophy. Most, but not of all, of the cardiac
enlargement took place between the first and second
echocardiograms: an increase in LV cavity volume was seen
between the second and third studies (5 ml/m2, P 5 0.055),
while an increase in mass index was seen between the third
and fourth studies (9 g/m2, P 5 0.05).
Two hundred and seventy-five of the 298 (92%) of the
patients still on dialysis had baseline and at least one repeat
echocardiogram. When the 29 patients with four echocar-
diograms were omitted, the mean change in mass index in
Table 1. Baseline characteristics
Four consecutive
echocardiograms
PNo, N 5 404 Yes, N 5 29
Age years 51 (49, 52) 58 (54, 62) 0.02
Diabetic 28% 17% 0.2
Ischemic heart disease 22% 28% 0.4
Cardiac failure 32% 21% 0.2
Hypertension .10 years 36% 21% 0.09
Current smokers 27% 17% 0.3
Baseline echocardiographic
classification
Normal 21% 33%
Concentric LV hypertrophy 35% 37%
LV dilation 27% 30%
Systolic dysfunction 16% 0% 0.5
Left atrial dimension mm 39 (38, 39) 37 (35, 40) 0.4
Fractional shortening % 34 (33, 35) 37 (33, 40) 0.07
Left ventricular mass index g/m2 149 (145, 154) 128 (119, 138) 0.02
Left ventricular cavity volume
index ml/m2
85 (81, 89) 73 (64, 83) 0.1
Mass/volume ratio g/ml 1.9 (1.9, 2.0) 1.8 (1.7, 2.0) 0.5
Interval variables are presented as mean values with 95% confidence
intervals in parentheses. LV is left ventricle.
Table 2. Characteristics of the 29 patients with four consecutive
echocardiograms while on dialysis therapy, expressed as the mean of
each variable (which were measured on a monthly basis)
Variable
Mean
(95% Confidence interval)
Systolic blood pressure mm Hg 147 (141, 153)
Diastolic blood pressure mm Hg 80 (76, 84)
Number of antihypertensives 0.7 (0.6, 0.8)
Proportion due to
Calcium-channeal blockers 0.34
Beta-blockers 0.32
ACE-inhibitors 0.15
Vasodilators 0.12
Centrally-acting agents 0.05a
Mode of dialysis therapy
Hemodialysis 20/29 (69%)
Peritoneal dialysis 9/29 (31%)
Blood urea mmol/liter 28 (26, 30)
Serum creatinine mmol/liter 1004 (928, 1080)
Serum albumin g/dl 3.8 (3.7, 3.9)
Hemoglobin g/dl 8.7 (8.3, 9.1)
Calcium mmol/liter 2.4 (2.2, 2.6)
Phosphate mmol/liter 1.9 (1.7, 2.1)
Interdialytic weight gain kg,
hemodialysis patients only
2.3 (1.9, 2.7)
a Proportions don’t add up to 1 because of rounding error
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the first year was 2 g/m2 and the mean change in cavity
volume was 1 ml/m2. Looking at patients with baseline mass
index less than 138 g/m2 and volume index less than 83
ml/m2 (the upper bounds of the 95% confidence intervals of
the subset of 29 patients with 4 echocardiograms), the
mean increments were 22 g/m2 (19%) and 14 ml/m2 (24%),
respectively.
Associations of left ventricular enlargement
The mean hemoglobin, serum albumin and blood pres-
sure values and the predominant mode of dialysis in the
interval between each echocardiogram are shown in Table
3. The associations of progressive left ventricular enlarge-
ment in each of the time intervals are shown in Table 4. On
bivariate analysis, the use of hemodialysis versus peritoneal
dialysis (41 g/m2, P 5 0.008) and anemia (10 g/m2 per 1 g/dl
drop in hemoglobin, P 5 0.02) were associated with
progressive LV enlargement within the first year of therapy
(Fig. 1). Neither variable demonstrated statistical associa-
tion when both were entered together in a multiple regres-
sion model, most likely because of a combination of
relatively few observations and a high degree of co-linearity
(r 5 0.47,1.5 g/dl higher in peritoneal dialysis patients, P 5
0.01) between the mode of dialysis and hemoglobin level
(Table 5). The LV enlargement seen after year 1 was
independent of anemia, blood pressure, serum albumin and
mode of dialysis.
Fig. 1. Scatter-plot of the change in left ventricular mass index from the
baseline to the first annual echocardiogram on the y-axis against the
mean hemoglobin level during this time interval on the x-axis. Symbols
are: (F) hemodialysis subjects; (E peritoneal dialysis subjects. The corre-
lation co-efficient is 0.46 (P 5 0.02) for hemoglobin level and 0.50 (P 5
0.008) for mode of dialysis therapy.
Table 3. Evolution of echocardiographic parameters
Baseline
Change from 1st
to 2nd
echocardiogramb
Change from
2nd to 3rd
echocardiogramb
Change from
3rd to 4th
echocardiogramb
P for
trenda(95% confidence interval)
Left atrial dimension 37 0 21 1 0.6
mm (35, 40) (21, 2) (22, 1) (21, 2)
P 0.5 0.3 0.5
Fractional shortening 37 21.6 20.9 0.8 0.4
% (33, 40) (25.8, 2.6) (23.0, 1.2) (21.1, 2.6)
P 0.4 0.4 0.4
LV mass index 128 18 21 9 0.001
g/m2 (119, 138) (8, 28) (211, 10) (0, 20)
P 0.001 0.8 0.05
LV cavity volume index 73 13 5 22 0.001
ml/m2 (64, 83) (4, 23) (0, 10) (28, 5)
P 0.006 0.055 0.6
Mass/volume ratio 1.83 0.01 20.03 20.05 0.5
g/ml (1.76, 1.91) (20.13, 0.16) (20.15, 0.10) (20.01, 0.01)
P 0.8 0.7 0.5
a Using repeated measures analysis of variance, this is a P for trend from one measure to the next
b The P values are Bonferroni-corrected for multiple comparisons
Table 4. Serial treatment variables, average of each monthly value
measured from one echocardiogram to the next
From 1st to
2nd
echocardiogram
From 2nd to
3rd
echocardiogram
From 3rd to
4th
echocardiogram
(95% confidence interval)
Hemoglobin g/dl 8.6 8.2 8.3
(8.1, 9.2) (7.7, 8.9) (7.6, 8.9)
Serum albumin g/dl 3.8 3.8 3.8
(3.7, 3.9) (3.7, 3.9) (3.7, 4.0)
Systolic blood
pressure mm Hg
147 149 150
(140, 155) (141, 157) (143, 158)
Diastolic blood
pressure mm Hg
81 80 79
(79, 85) (76, 84) (75, 83)
Hemodialysis/
peritoneal dialysis
69%/31% 69%/31% 69%/31%
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DISCUSSION
The patient subset used in this report clearly is highly
self-selected. The major selection factors are probably
related to older age, which may have lowered the chance of
receiving a renal transplant, lower cardiac mass that ap-
peared to increase longevity on dialysis therapy [5, 9, 12],
and compliance. With regard to the latter, the mean
interval from inception of dialysis therapy to the fourth
echocardiogram was 43.5 months. Ninety-one patients
overall remained in the study at this time. Twenty-nine of
91 or 32% represents a 68% chance of having each of three
technically successful scheduled echocardiograms after the
baseline echocardiogram (which was a study inclusion
criterion).
Balanced against the highly-selected composition of the
patient population is the increased ability to detect change,
because each patient acts as his or her control throughout.
We observed very clear increases in left ventricular cavity
volume and mass index. The ratio of mass-to-volume,
however, remained constant, suggesting that progressive
left ventricular dilation with compensatory hypertrophy is
the major long-term evolutionary pattern in dialysis pa-
tients. Most, but not all, of the left ventricular enlargement
took place within the first year. Anemia and the use of
hemodialysis as opposed to peritoneal dialysis were asoci-
ated with left ventricular enlargment, but only within the
first year of dialysis therapy. The left ventricular enlarge-
ment seen after one year was numerically smaller, and
appeared to take place autonomously of mode of dialysis
therapy, blood pressure, serum albumin and hemoglobin
levels. Taken together, these data suggest that the thera-
peutic window for intervention to prevent progressive
cardiac enlargement does not remain open much beyond
one year.
It is well known that most patients with end-stage renal
disease have left ventricular dilation, left ventricular hyper-
trophy or systolic dysfunction. There is an accumulating
literature to suggest these changes in cardiac morphology
and function accelerate rapidly as renal function declines in
the pre-end-stage renal disease era [6–8]. This study
suggests that the process of progressive left ventricular
hypertrophy, particularly in response to left ventricular
dilation, continues after the institution of dialysis therapy,
especially in the first year. Similar findings were in a study
of 11 peritoneal dialysis patients by Huting and Alpert [13].
In their study, a follow-up echocardiogram was performed
after an interval of 34 months. Left ventricular mass
increased from 234 to 299 g (P , 0.05); however, mass-to-
volume ratios increased from 1.28 to 1.85 g/ml (P , 0.001),
suggesting that progressive wall thickening was the pri-
mary evolutionary pattern [13]. Covic et al described the
echocardiographic findings in a cross-sectional study of
30 patients on ten or more years of long-hour (24 hr per
week dialysis schedule) hemodialysis [14]. They found
left ventricular hypertrophy in 76%. In contrast to our
study only 10% had left ventricular dilation, suggest-
ing that wall thickening was the primary pathological
process [14].
The major factors associated with progressive LV en-
largement in our study were the use of hemodialysis as
opposed to peritoneal dialysis and anemia. The creation of
fistulae in ESRD patients is known to lead to increased
cardiac pre-load, which is usually offset by increased stroke
volume [15], and the short-term trade-off for such an
adaptative LV dilation is increased wall tension and oxygen
demand according to the Law of Laplace. Very large A-V
fistulae have been associated with development of cardiac
failure that resolved after the fistula was closed [16–18].
London et al have reported that LV dilation is the most
characteristic abnormality of normotensive hemodialysis
patients without cardiac disease; the degree of LV dilation
was related to anemia and the hemodynamic effect of the
fistula [19]. There have been few studies comparing the
long-term effects of hemodialysis and peritoneal dialysis on
cardiac structure and function, although it is possible that
the continuous nature of peritoneal dialysis offers theoret-
ical hemodynamic advantages, including avoidance of
marked swings in extracellular fluid volume, which may
have adverse effects on long-term cardiac function.
Many studies have examined the effect of partial correc-
tion of renal anemia using recombinant human erythropoi-
etin. These studies have consistently shown a partial regres-
sion of LV dilation and/or LV hypertrophy. This may
account for the associations between anemia, cardiac fail-
ure and mortality in dialysis patients [20–35].
There was no association between either systolic or
diastolic blood pressure and progressive LV hypertrophy in
our highly selected subset of patients. It is worth pointing
out that average blood pressure levels were probably better
than those typically seen in dialysis patients. Similar com-
ments could be made about phosphate and albumin levels,
suggesting that this was a relatively healthy and/or more
Table 5. Correlation-regression analysis between changes in left
ventricular (LV) mass index and serial treatment variables
Outcome variable, change in LV mass index
From 1st to 2nd
echocardiogram
From 2nd to 3rd
echocardiogram
From 3rd to 4th
echocardiogram
Hemoglobin g/dl r 5 0.46 NS NS
b 5 212 g/m2
P 5 0.02
Serum albumin
g/dl
NS NS NS
Systolic blood
pressure mm Hg
NS NS NS
Diastolic blood
pressure mm Hg
NS NS NS
Hemodialysis vs.
peritoneal
dialysis
r 5 0.50 NS NS
b 5 41 g/m2
P 5 0.008
Foley et al: Cardiomyopathy in dialysis patients 1723
compliant group of patients. Also, the range of average
blood pressures in this subset was narrow, which limits the
possibility of showing an association between blood pres-
sure and progressive cardiac enlargement. We have previ-
ously shown that hypertension was associated with cardiac
enlargement in the overall patient group, a group with both
a higher average and a higher variability in blood pressures
[5, 9, 36]. Several recent studies also support the notion that
hypertension and left ventricular hypertrophy are associ-
ated in end-stage renal disease [6, 7, 37].
Our study is limited by small patient numbers and the
highly selected nature of its subjects. There was no attempt
made at systematic collection of indices of dialysis ade-
quacy, which reflects the treatment practices in use when
the study began in the early 1980s. Despite its limitations,
our study is likely to be unique for the number of echocar-
diograms performed in sequence, given that patient “loss”
to transplant or death is so rapid. The data presented here
strongly suggest that progessive cardiac enlargement, par-
ticularly LV dilation with compensatory hypertrophy, con-
tinue after starting dialysis therapy. Most of the additional
cardiac enlargement occurred in the first year of dialysis
therapy. This observation, coupled with the observation
that the cardiac enlargement occurring after this time point
was independent of the most commonly measured deter-
minants of cardiac work, suggests that intervention beyond
one year may be relatively ineffective.
Reprint requests to Robert N. Foley, M.B., Division of Nephrology,
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